Erschienen in:
13.05.2016 | Letter to the Editor
Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: What is missing?
verfasst von:
Nuggehally R. Srinivas
Erschienen in:
Cancer Chemotherapy and Pharmacology
|
Ausgabe 5/2016
Einloggen, um Zugang zu erhalten
Excerpt
Fox et al. report an interesting pharmacokinetic/pharmacodynamic study of tariquidar, a potent Pgp inhibitor, in combination with three cytotoxic drugs agents namely docetaxel, vinorelbine, and doxorubicin [
1]. The functional tracking of the ability of tariquidar to block Pgp efflux was monitored using rhodamine assay in the PBMCs prepared from the blood samples of patients, and the pharmacodynamic activity was measured by
99mTc-sestamibi scintigraphy imaging in tumors [
1]. …